Periventricular hyperintensities are associated with elevated cerebral amyloid
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 1, 2015
- Accepted in final form October 19, 2015
- First Published January 8, 2016.
Article Versions
- Previous version (January 8, 2016 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Michael Marnane, MD, PhD,
- Osama O. Al-Jawadi,
- Shervin Mortazavi,
- Kathleen J. Pogorzelec, BSc,
- Bing Wei Wang, MD,
- Howard H. Feldman, MD,
- Ging-Yuek R. Hsiung, MD, MHSc;
- For the Alzheimer's Disease Neuroimaging Initiative
- Michael Marnane, MD, PhD,
NONE
NONE
(1) American Academy of Neurology fellow travel award (2) Alzheimer Association International Conference fellow travel award
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Heart and Stroke Foundation of Canada (fellowship salary award)
NONE
NONE
NONE
NONE
NONE
NONE
- Osama O. Al-Jawadi,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Shervin Mortazavi,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kathleen J. Pogorzelec, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bing Wei Wang, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Howard H. Feldman, MD,
1. Commercial; Eli Lilly and Co: SAB 2. Commercial; Biogen Idec: SAB 3. Commercial Genentech: DMC 4. Commercial Eisai LTD: DSMB 5. Commercial ISIS Pharmaceuticals: Advisory Board 6. Commercial Arena Pharmaceuticals: Advisory Board Payments from Commercial Organizations to UBC 6. Not for Profit: Tau Consortium: SAB honoraria
NONE
1. Not for Profit: Tau Consortium Investigator Meetings 2015 2. Not for Profit: New York Academy of Sciences and US Against Alzheimer's Disease 2013 and 2014 (travel expenses) 3. Not for Profit: Alzheimer Society of Canada 2015 (travel expenses) 4. Not for Profit: US Alzheimer Association 2015 4. Not for Profit: Brain Canada 2014 (travel expenses)
NONE
US Serial Number PCT/2007/070008 Detecting and Treating Dementia
Royalties from the book Atlas of Alzheimer?s Disease (2007) Informa Health London
NONE
1. Commercial Arena Pharmaceuticals LTD: 2014
NONE
NONE
NONE
NONE
1. Canadian Institutes of Health Research CIHR # 287674 (2013-18)role co Principal Investigator, 2. CIHR Consortium for Neurodegeneration and Aging co Principal Investigator (2014-19), 3. CIHR Canadian Pipeline for AD Therapeutics 2015 Principal Investigator (2015-16)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ging-Yuek R. Hsiung, MD, MHSc;
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Hsiung has received research support as a clinical trials site investigator from Eli Lilly, Hoffman-La Roche, and TauRx, and has received honorarium for participation in expert review committee with Merck and Eli Lilly.
Dr. Hsiung has provided investigator's report to the British Columbia Ministry of Health on the Alzheimer Disease Therapeutic Initiative.
Dr. Hsiung is supported by a Clinical Genetics Investigatorship award from the CIHR, and has received research funding from the CIHR, Alzheimer Society of Canada, and NIH.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- For the Alzheimer's Disease Neuroimaging Initiative
- From the Clinic for Alzheimer Disease and Related Disorders, Djavad Mowafaghian Center for Brain Health (M.M., O.O.A.-J., S.M., K.J.P., B.W.W., H.H.F., G.-Y.R.H.), and Department of Medicine, Division of Neurology (M.M., H.H.F., G.-Y.R.H.), University of British Columbia, Vancouver, Canada.
- Correspondence to Dr. Marnane: michael.marnane{at}vch.ca
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Research Article
Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at AutopsyMichel J. Grothe, Alexis Moscoso, Nicholas J. Ashton et al.Neurology, July 15, 2021 -
Article
Plasma tau in Alzheimer diseaseNiklas Mattsson, Henrik Zetterberg, Shorena Janelidze et al.Neurology, September 30, 2016 -
Articles
Vascular burden and Alzheimer disease pathologic progressionRaymond Y. Lo, William J. Jagust et al.Neurology, September 12, 2012 -
Article
Patterns of longitudinal cortical atrophy over 3 years in empirically derived MCI subtypesEmily C. Edmonds, Alexandra J. Weigand, Sean N. Hatton et al.Neurology, May 11, 2020